BLOG
From PHQ-9 to P&L: Quantifying the Financial Impact of Behavioral Health Outcomes
Outcomes That Move Cost
What if improving depression outcomes could reduce total cost of care by more than 20% at scale?
Healthcare has made significant strides in expanding access to behavioral health services. Yet, one persistent challenge remains: translating clinical improvement into economic value. Access alone has not been enough to bend the cost curve. What matters is whether care leads to measurable outcomes, and, critically, whether those outcomes translate into financial impact.
This is where Array distinguishes itself. Array is not simply expanding access to care. Operating at the intersection of clinical quality and financial performance, Array provides something healthcare leaders have long needed: a clear, defensible link between improved mental health and reduced total cost of care.
For executives accountable to CFOs, boards, and payer partners, outcomes without economic translation fall short. What’s required is a credible, data-backed narrative that connects clinical gains to per-member-per-year (PMPY) savings. Until recently, behavioral health has lacked this bridge.
The Missing Link: Translating PHQ Improvement into Dollars
A growing body of evidence now makes that translation possible. Most notably, Maeng’s cost impact model establishes a clear relationship between depression improvement and total healthcare costs.
The findings are striking:
1Patients achieving clinically significant improvement (≥50% reduction in PHQ-9) experience 36% lower total cost of care compared to those with no improvement.
2Smaller improvements, while clinically positive, do not meaningfully reduce cost.
3Each 1-point increase in PHQ-9 score is associated with ~3.5% higher monthly healthcare costs.
The implication is clear: crossing the threshold into clinically meaningful improvement is what unlocks economic value.
As described in our recent Clinical Outcomes Report, Array’s real-world outcomes across thousands of patients demonstrate consistent movement beyond this threshold:
1Average PHQ‑9 scores improve from 10.4 to 6.2 (a 4.2-point, ~40% reduction)
2Among higher-acuity patients changes are even larger: 15.8 to 8.5 (a 7.3-point, ~46% reduction)
3Approximately (60) 43% of patients achieve clinically significant improvement (≥50% reduction in PHQ‑9)
In other words, Array is not just improving symptoms. Instead, we are reliably moving a substantial portion of patients into the range where cost reductions occur.
From Clinical Improvement to PMPY Impact
Continuous model (directional):
- A 4.2-point PHQ reduction corresponds to roughly ~15% lower total cost of care
- A 7.3-point reduction (high-acuity population) corresponds to approximately ~25% cost reduction
Threshold model (most defensible):
- With ~43%-47% of patients achieving clinically significant improvement, and those patients realizing ~36% savings
- The weighted population impact is approximately: .43 × 36% = ~15% total cost reduction for all patients and .47 x 36% = ~17% among higher-acuity patients
To translate this into executive-relevant terms:
- Assuming a conservative baseline of $12,000 PMPY total cost of care
- A 20% reduction equates to approximately $2,400 PMPY in savings
- Across a population of 10,000 members, that represents a $24 million annual savings opportunity
This is the “aha” moment for decision-makers. It transforms behavioral health from a cost center into a lever for measurable financial performance. And this lever can be modeled, forecasted, and embedded into value-based contracts.
Why This Matters: Choosing the Right Partner
Healthcare is in the midst of a fundamental shift from volume to access, and now from access to outcomes-driven value. Behavioral health sits at the center of this transformation. Array is demonstrating that clinically meaningful outcomes can reliably translate into financial performance at scale.
For organizations accountable for total cost of care, mental health is no longer ancillary. It is a primary cost driver and a powerful opportunity for cost reduction.
But not all solutions are created equal. Executives need partners who can:
- Deliver consistent, measurable outcomes
- Perform at scale across diverse populations
- Translate clinical results into PMPY savings and population-level financial impact
The distinction is subtle but critical: The difference between a 40% improvement and a 50% improvement in PHQ‑9 can be the difference between no material savings and meaningful cost reduction.
Array is purpose-built to deliver on this threshold:
- Measurement-based care ensures outcomes are tracked and optimized
- Stratified care pathways match treatment intensity to patient need
- Integrated coordination supports sustained improvement
The result is not just better care, but care that produces financially meaningful outcomes.
The Strategic Takeaway
The question is no longer whether behavioral health impacts total cost of care.
The evidence is clear: when patients improve meaningfully, costs fall.
The real question is: Which partners can deliver that improvement consistently and prove it at scale?
Array offers a compelling answer.
By combining clinical rigor with economic clarity, Array enables healthcare organizations to turn behavioral health into a strategic advantage, in which outcomes are not just measured, but monetized.
In a healthcare system increasingly defined by value, outcomes are the currency and clinically meaningful improvement is what unlocks it.
References
Chief Medical Officer at Array Behavioral Care
Sara Gotheridge, MD, is the Chief Medical Officer at Array Behavioral Care, where she leads the clinical team and oversees the quality program. With a 25-year career dedicated to expanding behavioral healthcare practices, Dr. Gotheridge brings deep expertise in integrated care, having previously held leadership roles at LifeStance Health and Trilogy Behavioral Healthcare.